He had no celebrity investors, no massive marketing budget, and was trying to sell clinicians on a concept most had never heard of. What Kiran Krishnan had was the science, the conviction, and the willingness to spend years on the road teaching doctors and practitioners about a revolution that had not yet arrived. It arrived, and built one of the most respected microbiome companies in modern healthcare.
The year was 2013, and Kiran Krishnan was standing in front of a room of healthcare practitioners trying to explain something that most of them found difficult to take seriously: that the trillions of bacteria living in the human gut were not just passengers, but active participants in virtually every system in the body, immunity, metabolism, skin health, hormonal regulation, even cognition and mood.
Most of the clinicians in the room were politely skeptical. A few were openly dismissive. The mainstream medical community had not yet caught up to what the research was already showing, and the word ‘microbiome’ had not yet entered the cultural conversation. Krishnan kept going anyway.
That decision, to build a company around a scientific concept before the market understood it, with minimal outside capital and a strategy rooted in education rather than advertising, became the foundation of Microbiome Labs, one of the world’s leading microbiome companies in functional medicine and healthcare. The company’s growth trajectory, which ended in a nine-figure exit, was not driven by viral marketing or celebrity endorsements. It was driven by the conviction that if you teach people to genuinely understand something, they will act on it.
The Scientist Who Refused to Stay in the Lab
Krishnan was trained in research microbiology at the University of Iowa, but he recognized early that the traditional academic path, publish papers, apply for grants, advance within an institution, was not where he wanted to direct his energy. What fascinated him was not the science in isolation, but the gap between what science was discovering and what was actually reaching patients.
That gap, in his observation, was enormous. Breakthrough research was sitting in journals, waiting years or decades to translate into clinical practice, while the patients who could benefit from it were receiving care based on what was understood a generation ago. He saw entrepreneurship as the fastest vehicle for closing that gap, not as a substitute for scientific rigor, but as a mechanism for accelerating its real-world impact.
Over the past 24 years, Krishnan has designed and overseen more than 35 human clinical trials, become a named inventor on multiple U.S. and international patents, and authored peer-reviewed publications and book chapters on microbiome science. He has also lectured to more than 100,000 healthcare practitioners across the globe, a number that reflects both the scale of his educational mission and the role that mission played in building the businesses he helped create.
“Understanding is believing, and believing breeds action. If you can teach someone to genuinely understand a scientific concept, they will act on it. That is not just a business philosophy, it is a theory of how scientific revolutions actually spread.” – Kiran Krishnan
Building a Business Around What Nobody Believed Yet
When Microbiome Labs launched, the company faced a challenge that is specific to science-first ventures: the product’s value proposition depended on the customer understanding something they had not previously been taught. You could not simply run an ad. You had to change how people thought about human biology first.
Krishnan’s response was to turn education into the company’s primary growth engine. He traveled constantly, speaking at functional medicine conferences, hosting practitioner training sessions, answering clinical questions, and making himself available to the healthcare professionals who were trying to make sense of what the research was showing. The conversations built trust, the trust built relationships, and the relationships built the business. Microbiome Labs grew not through paid acquisition but through a practitioner network that believed in the science because someone had taken the time to explain it thoroughly.
That approach also shaped the product development philosophy. Rather than formulating products based on what would sell, Krishnan and the Microbiome Labs team built around genuine clinical problems, specific gaps between what patients needed and what existing options provided. The result was a line of probiotic, postbiotic, and synbiotic technologies widely adopted across functional medicine and integrative healthcare, continuing to generate clinical research long after they launched.
Identifying the Next Inflection Points
Krishnan’s entrepreneurial philosophy centers on a question he returns to consistently: “What important science exists today that will become standard practice tomorrow?” At Microbiome Labs, the answer was gut microbiome science and its systemic effects. Since then, he has applied the same framework to a portfolio of ventures that collectively map the emerging frontier of health science. EndoAxis Labs focuses on metabolic health and endocrine function. The Biome Learning Center provides practitioner education at scale. PhytoVeda US develops botanical innovations grounded in Ayurvedic science. SIV Care addresses skin health through microbiome-informed approaches.
Each venture begins from the same starting point: a scientific mechanism that has genuine clinical relevance, is not yet widely understood, and represents a significant opportunity to improve patient outcomes. The companies are different in focus, but they share the same operating logic, which is that the biggest opportunities in healthcare tend to cluster around concepts that are scientifically established but not yet culturally accepted.
The concepts Krishnan is currently focused on include gut barrier function, metabolic endotoxemia, systems biology approaches to chronic disease, AI-assisted formulation, and precision nutrition informed by microbiome data. Each of these, in his assessment, is where the microbiome was a decade ago: supported by compelling research, meaningful in clinical practice, and largely invisible to the mainstream healthcare conversation.
What a Nine-Figure Exit Actually Teaches You
The Microbiome Labs exit was validation of a thesis, not just about the company, but about the strategy behind it. Building with scientific integrity rather than chasing trends, investing in education rather than marketing, and developing genuine clinical trust rather than consumer buzz created something more durable than a fast-growing company. It created a category.
Krishnan is direct about what the exit represents and what it does not. The business success was a result of the philosophy, not the objective of it. Companies built primarily to be sold tend to optimize for metrics that look good in a pitch deck rather than for the deep clinical credibility that creates lasting value, and the irony is that doing the latter tends to produce better outcomes on both dimensions.
The Convergence Ahead
Krishnan sees the next decade as a period of significant acceleration. Artificial intelligence applied to microbiome data is beginning to enable precision nutrition and personalized interventions that were theoretically possible but practically out of reach a few years ago. Systems biology approaches are making it possible to understand chronic disease in ways that single-pathway pharmaceutical models cannot. And the public’s understanding of gut health, still incomplete but growing, is creating demand for solutions grounded in how the biology actually works.
His goal is to continue building companies that make complex biology understandable and actionable, and to help shift the center of gravity in healthcare from disease management toward resilience and prevention. That shift, in his view, represents one of the largest economic and human health opportunities of the next generation, and the entrepreneurs who build around it now, before it becomes obvious, will be the ones positioned to define what that future looks like. The gap between what the science shows and what the market understands is, as always, his starting point.
Kiran Krishnan is a research microbiologist, clinical researcher, entrepreneur, and scientific educator. He is the co-founder and former Chief Scientific Officer of Microbiome Labs, and the founder of EndoAxis Labs, The Biome Learning Center, PhytoVeda US, and SIV Care. He has overseen more than 35 human clinical trials, holds multiple U.S. and international patents, and has educated more than 100,000 healthcare practitioners worldwide.
